The phase 1 study is a randomized, double-blind, placebo-controlled, single and multiple ascending dose study intended to enroll up to 70 healthy volunteers to evaluate the safety and tolerability of BT-11. BT-11 is in development for treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease.
BT-11 is a small molecule investigational candidate that activates the lanthionine synthetase C-Like 2 (LANCL2) pathway, targeting the gastrointestinal tract. Growing research suggests that the LANCL2 plays an important role in the immunoregulatory process.
Based on preclinical and translational evidence, BT-11, by activating the LANCL2 pathway and modulating the interactions between immunological and metabolic signals in immune cells, creates a favorable regulatory microenvironment in the gut, decreasing the production of key inflammatory mediators and increasing anti-inflammatory molecules within the site of inflammation.
Landos is focused on the discovery and development of first-in-class oral therapeutics for patients with autoimmune diseases.
Diamyd Medical granted US FDA Fast Track designation for Diamyd diabetes treatment
Ono partners with Shattuck Labs for bifunctional fusion proteins
Artax Biopharma doses first subject in AX-158 Phase 2a psoriasis trial
Bio-Thera Solutions commences dosing in BAT6026 Phase IA/IIB clinical trial
BioSenic expands patent coverage for ATO therapeutic platform
Celltrion USA submits CT-P47 Biologics License Application to FDA
NS Pharma's NS-229 receives European Commission orphan drug designation
Kyverna Therapeutics' KYV-101 granted US FDA fast track designation
InnoCare Pharma receives U.S. FDA clearance for ICP-248 clinical trial
Biosenic finalises agreement with Phebra for oral arsenic troxide development
Guangzhou Fermion Technology's FZ008-145 IND application receives Chinese regulatory approval
Allorion Therapeutics signs exclusive option and global license agreement with AstraZeneca